PLPeijuan Li

Peijuan Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Peijuan Li has a total of 16 co-authors. Here are the top co-authors by number of shared publications:

  • Dongping Yu

    Department of Emergency, The Second Affiliated Hospital of Dalian Medical University (Dalian Medical University Cancer Hospital), Dalian, Liaoning, China

    2 shared publications
  • Fei Li

    Department of General Surgery, Xuanwu Hospital, Capital Medical University

    2 shared publications
  • Ling Wang

    Department of Critical Care Medicine, Affiliated Hospital of Zunyi Medical University, Zunyi City, Guizhou Province, China

    2 shared publications
  • Ping Gong

    Department of Emergency Medicine, Shenzhen People’s Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), China

    2 shared publications
  • Yushu Chen

    Department of Emergency, Shenzhen People’s Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology) , Shenzhen, China

    2 shared publications
  • Zhen Fang

    Department of General Surgery, Xuanwu Hospital, Capital Medical University, Beijing, China

    2 shared publications

Latest Publications

  • Role of eCIRP in Mediating Post-ischemia Microglial Phagocytosis via TREM-2 Receptor: Insights from Porcine and Mouse Cellular Models

    by Peijuan Li, Zhangping Sun, Yushu Chen, Zhen Fang, Dongping Yu, Ling Wang, Yanbo Ren, Ping Gong

    Cerebral ischemia/reperfusion (I/R) injury triggers potent neuroinflammatory responses, in which microglial activation and dysregulated phagocytosis may contribute to neuronal damage. Extracellular cold-inducible RNA-binding protein (eCIRP), a damage-associated molecular pattern, has been implicated in postischemic inflammation; however, its role in regulating microglial phagocytosis remains poorly understood. This study employed a porcine model of cardiac arrest/reperfusion (CA/R) and a mouse cellular model of oxygen–glucose deprivation/reoxygenation (OGD/R) in BV2 microglia and N2a neuron to investigate the role of the eCIRP–TREM2 signaling in microglial activation. We evaluated protein expression and direct interaction between CIRP and TREM2 by Western blotting, immunofluorescence, co-immunoprecipitation, and surface plasmon resonance (SPR), while assessing phagocytic activity by fluorescent microsphere uptake and synaptic protein expression assays. Both CA/R and OGD/R conditions significantly elevated the levels of CIRP expression and activation of the TREM2–DAP12–Syk–ERK1/2 signaling. Treatment with recombinant human CIRP (rhCIRP) further increased the expression of microglial activation markers and enhanced phagocytic activity, accompanied by reducing the expression of synaptic proteins. These effects were partially mitigated by CIRBP or TREM2 silencing, or ERK inhibition. Our findings support a novel hypothesis that eCIRP may bind to TREM2 and activate downstream signaling in microglia, enhancing their phagocytic responses in the process of I/R-induced neuronal injury. The eCIRP–TREM2 axis may thus represent a potential therapeutic target for modulating neuroinflammation and preserving neuronal integrity.


  • Open Access

    Oseltamivir Phosphate Modulates CD24‐Siglec‐G/10 Interaction to Suppress Microglial‐Driven Neuroinflammation After Cardiac Arrest

    by Yushu Chen, Ying Liu, Na Li, Ling Wang, Peijuan Li, Zhangping Sun, Dongping Yu, Ziren Tang, Ping Gong

    Background: In cardiac arrest (CA) patients undergoing cardiopulmonary resuscitation (CPR), neuroinflammation following return of spontaneous circulation (ROSC) contributes to brain ischemia/reperfusion injury and neurological dysfunction. Recent evidence suggested that neuraminidase could exacerbate inflammatory responses by disrupting CD24‐Siglec‐G/10 immune checkpoint axis. As a neuraminidase inhibitor, oseltamivir phosphate (OP) holds potential for immunomodulation beyond its antiviral use. We aimed to investigate the impact and mechanism of OP on neuroinflammation regulation after ROSC.Methods: Male pigs were randomized into the sham control group, CPR, and CPR + OP group. CA was induced in pigs through 8 min of untreated ventricular fibrillation. Brains were harvested for assessing serum inflammatory markers and neuronal damage at 24 h after ROSC. BV2 microglial underwent oxygen–glucose deprivation/reperfusion (OGD/R). Effects of OP on inflammatory responses, NF‐κB activation, cell viability, and the CD24‐Siglec‐G/10 interaction were evaluated using immunofluorescence, immunoprecipitation, molecular, and biochemical assays.Results: In vivo, OP attenuated pig cerebral microglial activation and neuronal integrity with attenuated neuroinflammation, alongside time‐dependent neuraminidase activity increases. In vitro, OP suppressed OGD/R‐induced microglial NF‐κB activation, reduced pro‐inflammatory cytokine levels, and preserved CD24‐Siglec‐G interaction, correlating with diminished neuraminidase release.Conclusions: OP as a repurposed immunomodulator that suppresses microglial‐driven neuroinflammation after CA by preserving sialylation‐dependent CD24‐Siglec‐G/10 interaction.


  • Open Access

    Combining Bulk RNA-seq and scRNA-seq data to identify RNA m5C methyltransferases NSUN1: a rising star as a biomarker for cancer diagnosis, prognosis and therapy

    by Zhen Fang, Peijuan Li, Fei Li

    Background: RNA 5-methylcytosine (m5C) methyltransferases NSUN1 is a member of the NOP2/SUN (NSUN) RNA methyltransferase family. Studies have found that the expression of NSUN1 is elevated in breast and colon cancer and can predict poor prognosis. However, the NSUN1 gene has only been studied in a few tumors. Methods: Single-cell RNA sequencing (scRNA-seq) and Bulk RNA-seq data were used for comprehensive analysis of NSUN1 in cancers. The Human Protein Atlas (HPA) database was used to identify the gene location. Immunofluorescence staining was used to detect NSUN1 subcellular distribution within the nucleus, endoplasmic reticulum (ER), and microtubules of A-431, U-2, U-251 cells. The cBioPortal tool was used to analyze the alteration frequency and mutation type. The epigenetic profile of NSUN1 also was analyzed by using the University of Alabama at Birmingham CANcer data analysis Portal (UCLCAN). Tumor mutation burden (TMB), microsatellite instability (MSI), and immune checkpoint expression in cancers were analyzed. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) were used to perform enrichment and visualization. The study was based on online resources and public databases. Results: Elevated NSUN1 expression had been observed in most human cancers. Analysis of scRNA-seq data showed that NSUN1 was highly expressed in immune cells such as T cells, B cells, and dendritic (DC) cells. High NSUN1 expression indicated poor overall survival (OS) and disease-free survival (DFS). The characteristics of genetic alteration, methylation and phosphorylation of NSUN1 were analyzed and higher levels of phosphorylation in tumor tissues were found. In addition, the expression of NSUN1 was closely related to tumor-infiltrating immune cells. At the same time, the expression of NSUN1 was positively correlated with the expression of multiple immune checkpoints. Conclusions: The gene expression profile, survival status, genetic alteration, methylation, phosphorylation and infiltrating immune cells of NSUN1 in human cancers were comprehensively analyzed. The results herein implied that NSUN1 may be an effective biomarker for early cancer diagnosis, prognosis and therapy.


  • Open Access

    Roles of exosomes as drug delivery systems in cancer immunotherapy: a mini-review

    by Zhen Fang, Yixuan Ding, Zhigang Xue, Peijuan Li, Jia Li, Fei Li

    Exosomes can be released by a variety of cells and participate in intercellular communication in many physiological processes in the body. They can be used as carriers of cancer therapeutic drugs and have natural delivery capabilities. Some biologically active substances on exosomes, such as major histocompatibility complex (MHC), have been shown to be involved in exosome-mediated anticancer immune responses and have important regulatory effects on the immune system. Exosome-based drug delivery systems hold great promise in future cancer immunotherapy. However, there are still substantial challenges to be overcome in the clinical application of exosomes as drug carriers. This article reviews the biological characteristics of exosome drug delivery systems and their potential applications and challenges in cancer immunotherapy.